Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
50
resultados
Última actualización
13/01/2026 [06:45:00]
Resumen de: AU2024302737A1
The present disclosure provides for a chimeric antigen receptor (CAR) polypeptide comprising a CD74 antigen binding domain, a transmembrane domain, an intracellular signaling domain, and a co-stimulatory signaling region. Further provided herein is an isolated nucleic acid encoding the recombinant polypeptide as disclosed herein, a vector comprising the isolated nucleic acid, and a cell comprising the vector. Also provided herein is a method of treating lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the chimeric antigen receptor polypeptide as disclosed herein. Further described herein is a method of reducing tumor activity in a subject with lymphoma, the method comprising administering to the subject a therapeutically effective amount of the chimeric antigen receptor polypeptide as described herein.
Resumen de: WO2026007901A1
The present invention relates to an FLT3-CAR-γδT cell co-expressing a cytokine and a use thereof. Specifically, the present invention provides an engineered CAR-γδT cell targeting FLT3, wherein the CAR-γδT cell co-expresses an IL-2 or IL-7 cytokine, maintains a high stemness level and proliferation capacity, and has a sustained tumor cell killing ability. The FLT3-CAR-γδT cell co-expressing a cytokine of the present invention demonstrates persistent killing ability and anti-tumor activity against acute myeloid leukemia (AML) tumor cells in multiple in vitro and in vivo experiments, has high safety and wide applicability, and has application prospects in the field of AML therapy.
Resumen de: WO2026007326A1
A compound as shown in general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and the use thereof in cancer-related diseases such as acute myeloid leukemia. The synthesized vinblastine derivative has an antiproliferative activity against acute myeloid leukemia cancer cells that is significantly superior to that of vinblastine, can be used as a toxin molecule in the development of antibody-drug conjugates, and has a great anti-tumor effect.
Resumen de: WO2026007411A1
An anti-IL1RL1/IL-33/NF-kB antibody and a method for treating acute myeloid leukemia using same. The anti-IL1RL1/IL-33/NF-kB antibody comprises an anti-IL1RL1 antibody, an anti-IL-33 antibody, and an anti-NF-kB antibody. The treatment method comprises: step 1, patient assessment and diagnosis; step 2, antibody selection and preparation; step 3, treatment plan formulation; step 4, antibody administration; step 5, efficacy monitoring and assessment; and step 6, subsequent treatment and follow-up. The combined use of the anti-IL1RL1 antibody, the anti-IL-33 antibody, and the anti-NF-kB antibody for treating AML can inhibit the proliferation and survival of AML cells at multiple levels by means of simultaneously blocking the IL-33/IL1RL1 signaling pathway and NF-kB activation, thereby improving the therapeutic effect.
Resumen de: AU2024279967A1
The present disclosure relates to CD19 CAR-T cell products and methods of treating relapsed or refractory CD19+ haematological malignancies.
Resumen de: MX2025012459A
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering therapeutically effective amounts of a BCMAxCD3 bispecific antibody and a GPRC5DxCD3 bispecific antibody to the subject.
Resumen de: EP4674432A1
Provided are a method and a use for treating cancers by using a CD20/CD47 double-blocking bifunctional fusion protein in combination with a bifunctional alkylating agent, in particular a method and a use for treating cancers (especially non-Hodgkin lymphoma) by using a CD20/CD47 double-blocking bifunctional fusion protein in combination with bendamustine or a salt thereof.
Resumen de: WO2026006528A1
The present disclosure provides modified stem cells, in particular hematopoietic stem cells engineered to express a variant of a B-cell lymphoma 2 (Bcl-2) family protein, wherein the variant confers resistance to a cytotoxic inhibitor of the Bcl-2 family protein. Also provided are methods and uses of the modified cells for therapeutic applications.
Resumen de: WO2026006425A1
Disclosed herein are compounds of the Formula: (I), as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to treat a cancer, such as leukemia. Also provided are methods of administering compounds and compositions provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders.
Resumen de: WO2026006187A1
Disclosed herein is a compound that has properties to treat a subject with T cell lymphoma as compared to conventional interferon. In addition, methods to use such compound to treat T-cell lymphoma are also disclosed.
Resumen de: WO2026006238A1
A method of obtaining a prognosis for a subject who has or has had leukemia who has been or is being treated with a tyrosine kinase inhibitor (TKI) is described. The method includes determining the levels of one or more of 1) total N6-methyladenosine (m6A), 2) long non-coding RNA (lncRNA) bearing m6A sites, 3) lncRNA-specific m6A, 4) the fat mass and obesity-associated gene (FTO) in a biological sample from the subject; and assigning a poor prognosis or poor TKI responder status to the subject if the level of m6A, lncRNA being m6A sites, lncRNA-specific m6A, and/or FTO is higher than the one or more corresponding control values obtained from a healthy subject. Methods of treating a subject having TKI-resistant leukemia and methods of predicting TKI resistance in a subject having leukemia are also described.
Resumen de: WO2026002032A1
Disclosed in the present invention are a PIM kinase inhibitor as shown in general formula II, a pharmaceutical composition thereof, a preparation method therefor and the use thereof in the preparation of a drug for preventing and/or treating indications related to a PIM signaling pathway. The compound of the present invention is an ideal PIM kinase inhibitor with a high activity, which can be used for treating and/or preventing diseases including autoimmune diseases and tumors, e.g., inflammatory bowel disease, hematologic malignancies such as acute myeloid leukemia, myelofibrosis and chronic lymphocytic leukemia, and solid tumors such as gastric cancer and prostate cancer.
Resumen de: WO2026001924A1
Provided in the present application is an antibody specifically binding to GPRC5D or an antigen-binding portion thereof. The present application further relates to a bispecific T cell engager or chimeric antigen receptor, etc., that comprises the antibody or the antigen-binding portion thereof, and the use thereof in the treatment of multiple myeloma.
Resumen de: WO2026006370A1
Anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and chimeric antigen receptors (CARs) are provided herein. Also provided are polynucleotides encoded the anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and CARs. The anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and CARs are useful for the prevention and/or treatment of cancer, such as multiple myeloma. Also provided is a combination therapy including administration of the anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and CARs with an IL-16 or an IL-15 agonist.
Resumen de: WO2026006413A1
This disclosure relates to methods and compositions for treating cancer including advanced solid tumor, a metastatic solid tumor or lymphoma using an inducible IL-12 prodrug.
Resumen de: WO2026001958A1
Provided are: an adeno-associated virus (AAV) vector, the AAV vector comprising a cytokine gene, and the cytokine being selected from any one or two or more of the following: IL3, GM-CSF, IL6, APRIL, and BAFF; an AAV vector combination comprising any two or three or more of said AAV vectors; and a method for constructing an acute myeloid leukemia xenograft non-human animal and a method for constructing a multiple myeloma xenograft non-human animal. In addition, further provided is another adeno-associated virus (AAV) vector, the AAV vector comprising a cytokine gene, and the cytokine being selected from any one or two or more of the following: IL2, IL3, IL6, IL15, THPO, SCF, and GM-CSF; further provided is an AAV vector combination comprising any two or three or more of said AAV vectors; and further provided is the use of the AAV vector and AAV vector combination in the construction of a humanized immune system non-human animal, as well as a method for constructing a humanized immune system non-human animal and a method for promoting the differentiation of human hematopoietic stem cells into CD14+ monocytes and CD66b+ granulocytes.
Resumen de: WO2026000128A1
A composition, comprising: multiple different decoy oligonucleotides configured to collectively hybridize to DNA molecules derived from a plurality of target genomic regions, wherein each genomic region in the plurality of target genomic regions is differentially methylated in diffuse large B cell lymphoma patients for whom chemotherapy is effective compared to in diffuse large B cell lymphoma patients for whom chemotherapy is ineffective.
Resumen de: WO2026000126A1
A composition, comprising: a plurality of different decoy oligonucleotides configured to collectively hybridize to a DNA molecule derived from a plurality of target genomic regions, wherein each genomic region of the plurality of target genomic regions is differentially methylated in diffuse large B-cell lymphomas compared to non-diffuse large B-cell lymphomas.
Resumen de: WO2026006456A1
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of mosunetuzumab as a monotherapy or in combination with lenalidomide.
Resumen de: WO2026006252A1
The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Top1i) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.
Resumen de: WO2026001931A1
Provided in the present application are a single-domain antibody specifically binding to GPRC5D, a bispecific T cell engager or chimeric antigen receptor, etc. containing the single-domain antibody, and the use thereof in the treatment of multiple myeloma.
Resumen de: EP4670735A1
A prodrug nanoparticle for targeted accumulation and activation (treatment) in tumor tissue, that consists of a Pt(IV) complex with the following formula:wherein R<sub>1</sub> und R<sub>2</sub> are the same or different branched or unbranched alkyls having at least 14 carbon atoms, a sonosensitizer and a biocompatible drug delivery system can be used to treat tumors and in particular metastases in a way that is well tolerated by the body. The prodrug nanoparticles according to the invention are particularly suitable for the treatment of mammary carcinomas, pancreatic carcinomas, prostate carcinomas, bronchial carcinomas, endometrial carcinomas, germ cell tumors, non-Hodgkin's lymphomas and malignant mesotheliomas and, in particular, colorectal carcinomas, and their respective metastases.
Resumen de: EP4670742A1
The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Topli) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.
Resumen de: WO2025261276A1
An anti-CD20 antibody-drug conjugate, use thereof in combination with a therapeutic agent for treating relapsed or refractory non-Hodgkin lymphoma, and a composition thereof. The present invention relates to the field of biopharmaceuticals. The combined use of the anti-CD20 antibody-drug conjugate and at least one additional therapeutic agent has better efficacy than existing clinical second-line standard therapies.
Nº publicación: WO2025265054A2 26/12/2025
Solicitante:
ARCUTIS BIOTHERAPEUTICS INC [US]
ARCUTIS BIOTHERAPEUTICS, INC
Resumen de: WO2025265054A2
Methods of treating a patient suffering from one or more of epidermal disorders of persistent inflammation—cell kinetics and differentiation disorders, epidermal disorders of persistent inflammation—altered reactivity disorders, disorders of the lips, oral, or vaginal mucosa, epidermal disorders of cohesion—vesicular and bullous disorders, cutaneous lymphomas, skin manifestations of rheumatologic diseases, hypomelanoses and hypermelanoses, or skin manifestations related to oncology treatments. The methods include topical administration of a pharmaceutical composition comprising a therapeutically effective amount of roflumilast.
BOPI
Sede Electrónica
